Customs, Excise and Gold Tribunal - Delhi
Glaxo India Ltd. vs Commissioner Of Central Excise on 26 July, 2000
Equivalent citations: 2001 (132) ELT 736 Tri Del
ORDER S.S. Kang, Member (J)
1\. The appellants filed this appeal against the Order-in-Appeal dated
31-10-1994. In the impugned order the formulations manufactured by the
appellants Salbutamol inhaler was held to be classifiable under sub-heading
3003.10 of the Central Excise Tariff Act, 1985 Patent or Proprietary
medicaments.
2\. The learned Counsel appearing on behalf of the appellant submits that the
product in question is a medicament other than Patent and Proprietary
medicaments falling under sub-heading 3003.20 of the Central Excise Tariff
Act, 1985. He submits that the Salbutamol Inhaler is specifically mentioned in
the Pharmacopoeia in India and the appellants were manufacturing this product
and on the packing of the product only 'house mark' of the appellant printed.
He submits that the Hon'ble Supreme Court in the case of Astra Pharmaceuticals
(P) Ltd. v. Collector of Central Excise, Chandigarh, reported in 1995 (75)
E.L.T. 214 (S.C.) held that 'House mark' and 'Brand name' are two different
concepts, and if, the medicines is cleared with the 'house mark' of the
manufacture, it does not establish any relationship between the marks and
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
manufacture, it does not establish any relationship between the marks and
medicines. Therefore, he prays that the appeal be allowed.
3\. Learned JDR appearing on behalf of the Revenue submits that the appellants
were clearing the product in question under their name 'Glaxo' and the word
'Glaxo' appearing on the level shows that the relationship between mark and
the medicines. He, therefore, prays that the appeal be dismissed.
4\. Heard both sides.
5\. In this case the issue is whether the product in question is classifiable
under Heading 3003.10 as Patent or Proprietary medicament or under Heading
3003.20 as claimed by the appellants.
6\. The Chapter Note-2 (ii) of Chapter 30 of Central Excise Tariff Act, 1985
reads as under :
" 'Patent or Proprietary medicaments' means any drug or medicinal preparation,
in whatever form, for use in the internal or external treatment of, or for the
prevention of ailments in human beings or animals, which bears either on
itself or on its container or both, a name which is not specified in a
monograph in a Pharmacopoeia, Formulary or other publications namely -
    (a)     The Indian Pharmacopoeia;
    (b)     The International Pharmacopoeia;
    (c)     The National Formulary of India;
    (d)     The British Pharmacopoeia;
    (e)     The British Pharmaceutical Codex;
    (f)    The United States Pharmacopoeia;
    (g)     The National Formulary of the U.S.A.; 
    (h)    The Dental Formulary of the U.S.A.;
    (i)    The Dental Formulary of the U.S.A. / and; 
    (j)    The State Pharmacopoeia of the U.S.S.R.
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
container or packing was used to project the image of manufacturer and it does
not establish any relationship between the marks and the medicines. Therefore,
it cannot be said to be Patent or Proprietary medicament. In view of the above
discussions, the impugned order is set aside and the appeal is allowed.
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
manufacture, it does not establish any relationship between the marks and
medicines. Therefore, he prays that the appeal be allowed.
3\. Learned JDR appearing on behalf of the Revenue submits that the appellants
were clearing the product in question under their name 'Glaxo' and the word
'Glaxo' appearing on the level shows that the relationship between mark and
the medicines. He, therefore, prays that the appeal be dismissed.
4\. Heard both sides.
5\. In this case the issue is whether the product in question is classifiable
under Heading 3003.10 as Patent or Proprietary medicament or under Heading
3003.20 as claimed by the appellants.
6\. The Chapter Note-2 (ii) of Chapter 30 of Central Excise Tariff Act, 1985
reads as under :
" 'Patent or Proprietary medicaments' means any drug or medicinal preparation,
in whatever form, for use in the internal or external treatment of, or for the
prevention of ailments in human beings or animals, which bears either on
itself or on its container or both, a name which is not specified in a
monograph in a Pharmacopoeia, Formulary or other publications namely -
    (a)     The Indian Pharmacopoeia;
    (b)     The International Pharmacopoeia;
    (c)     The National Formulary of India;
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
manufacture, it does not establish any relationship between the marks and
medicines. Therefore, he prays that the appeal be allowed.
3\. Learned JDR appearing on behalf of the Revenue submits that the appellants
were clearing the product in question under their name 'Glaxo' and the word
'Glaxo' appearing on the level shows that the relationship between mark and
the medicines. He, therefore, prays that the appeal be dismissed.
4\. Heard both sides.
5\. In this case the issue is whether the product in question is classifiable
under Heading 3003.10 as Patent or Proprietary medicament or under Heading
3003.20 as claimed by the appellants.
6\. The Chapter Note-2 (ii) of Chapter 30 of Central Excise Tariff Act, 1985
reads as under :
" 'Patent or Proprietary medicaments' means any drug or medicinal preparation,
in whatever form, for use in the internal or external treatment of, or for the
prevention of ailments in human beings or animals, which bears either on
itself or on its container or both, a name which is not specified in a
monograph in a Pharmacopoeia, Formulary or other publications namely -
    (a)     The Indian Pharmacopoeia;
    (b)     The International Pharmacopoeia;
    (c)     The National Formulary of India;
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
manufacture, it does not establish any relationship between the marks and
medicines. Therefore, he prays that the appeal be allowed.
3\. Learned JDR appearing on behalf of the Revenue submits that the appellants
were clearing the product in question under their name 'Glaxo' and the word
'Glaxo' appearing on the level shows that the relationship between mark and
the medicines. He, therefore, prays that the appeal be dismissed.
4\. Heard both sides.
5\. In this case the issue is whether the product in question is classifiable
under Heading 3003.10 as Patent or Proprietary medicament or under Heading
3003.20 as claimed by the appellants.
6\. The Chapter Note-2 (ii) of Chapter 30 of Central Excise Tariff Act, 1985
reads as under :
" 'Patent or Proprietary medicaments' means any drug or medicinal preparation,
in whatever form, for use in the internal or external treatment of, or for the
prevention of ailments in human beings or animals, which bears either on
itself or on its container or both, a name which is not specified in a
monograph in a Pharmacopoeia, Formulary or other publications namely -
    (a)     The Indian Pharmacopoeia;
    (b)     The International Pharmacopoeia;
    (c)     The National Formulary of India;
    (d)     The British Pharmacopoeia;
    (e)     The British Pharmaceutical Codex;
    (f)    The United States Pharmacopoeia;
    (g)     The National Formulary of the U.S.A.; 
    (h)    The Dental Formulary of the U.S.A.;
    (i)    The Dental Formulary of the U.S.A. / and; 
    (j)    The State Pharmacopoeia of the U.S.S.R.
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
manufacture, it does not establish any relationship between the marks and
medicines. Therefore, he prays that the appeal be allowed.
3\. Learned JDR appearing on behalf of the Revenue submits that the appellants
were clearing the product in question under their name 'Glaxo' and the word
'Glaxo' appearing on the level shows that the relationship between mark and
the medicines. He, therefore, prays that the appeal be dismissed.
4\. Heard both sides.
5\. In this case the issue is whether the product in question is classifiable
under Heading 3003.10 as Patent or Proprietary medicament or under Heading
3003.20 as claimed by the appellants.
6\. The Chapter Note-2 (ii) of Chapter 30 of Central Excise Tariff Act, 1985
reads as under :
" 'Patent or Proprietary medicaments' means any drug or medicinal preparation,
in whatever form, for use in the internal or external treatment of, or for the
prevention of ailments in human beings or animals, which bears either on
itself or on its container or both, a name which is not specified in a
monograph in a Pharmacopoeia, Formulary or other publications namely -
    (a)     The Indian Pharmacopoeia;
    (b)     The International Pharmacopoeia;
    (c)     The National Formulary of India;
    (d)     The British Pharmacopoeia;
    (e)     The British Pharmaceutical Codex;
    (f)    The United States Pharmacopoeia;
    (g)     The National Formulary of the U.S.A.; 
    (h)    The Dental Formulary of the U.S.A.;
    (i)    The Dental Formulary of the U.S.A. / and; 
    (j)    The State Pharmacopoeia of the U.S.S.R.
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
or which is a brand name, that is, a name or a registered trade mark under the
Trade and Merchandise Marks Act, 1958 (43 of 1958), or any other mark such as
a symbol, monogram, label, signature or invented words or any writing which is
used in relation to that medicine for the purpose of indicating or so to
indicate a connection in the course of trade between the medicine and some
person, having the right either as proprietor or otherwise to use the name or
mark with or without any indication of the identity of that person."
This product is specifically mentioned in the Pharmacopoeia of India.
7\. The contention of the Revenue is that the appellants were clearing this
product under their brand name which shows the relationship between the mark
and the medicines. Therefore, it is classifiable under Heading 3003.10 of
Central Excise Tariff.
8\. We find that the Hon'ble Supreme Court in the case of Astra
Pharmaceuticals (P) Ltd. v. Collector of Central Excise, Chandigarh, reported
in 1995 (75) E.L.T. 215 (S.C.) held that 'house mark' and 'brand name' are two
different concepts. The Hon'ble Supreme Court held that 'house mark' on the
